BR9812394A - Amino terminalmente truncado mcp-2 como antagonistas da quimiocina - Google Patents
Amino terminalmente truncado mcp-2 como antagonistas da quimiocinaInfo
- Publication number
- BR9812394A BR9812394A BR9812394-7A BR9812394A BR9812394A BR 9812394 A BR9812394 A BR 9812394A BR 9812394 A BR9812394 A BR 9812394A BR 9812394 A BR9812394 A BR 9812394A
- Authority
- BR
- Brazil
- Prior art keywords
- mcp
- terminally truncated
- amino
- chemokine
- truncated amino
- Prior art date
Links
- 102000019034 Chemokines Human genes 0.000 title abstract 3
- 108010012236 Chemokines Proteins 0.000 title abstract 3
- -1 amino mcp-2 Chemical compound 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 abstract 3
- 101710155833 C-C motif chemokine 8 Proteins 0.000 abstract 3
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 abstract 3
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Patente de Invenção: <B>"AMINO TERMINALMENTE TRUNCADO MCP-2 COMO ANTAGONISTAS DA QUIMIOCINA"<D>. A presente invenção se refere ao MCP-2 mutilado do terminal amino, carecendo de aminoácidos de terminal NH~ 2~ correspondendo aos resíduos de aminoácido 1, 1-2, 1-3, 1-4 ou 1-5 do MCP-2 natural e tendo atividade antagonística da quimiocina, assim como seq³ências de cDNA codificando os mesmos, seu uso em terapia e/ou diagnose de doenças, nas quais é necessária atividade antagonística dos efeitos da quimiocina, e composições farmacêuticas que compreendendo os mesmos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97116863A EP0906954A1 (en) | 1997-09-29 | 1997-09-29 | Amino-terminal truncated c-c chemokines as chemokine antagonist |
| EP97122471A EP0905240A1 (en) | 1997-09-29 | 1997-12-19 | Amino-terminally truncated c-c chemokines as chemokine antagonists |
| EP98104216A EP0905241A1 (en) | 1997-09-29 | 1998-03-10 | Amino-terminally truncated c-c chemokines as chemokine antagonists |
| PCT/EP1998/006142 WO1999016876A1 (en) | 1997-09-29 | 1998-09-28 | Amino-terminally truncated mcp-2 as chemokine antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9812394A true BR9812394A (pt) | 2000-09-12 |
Family
ID=8227408
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9812565-6A BR9812565A (pt) | 1997-09-29 | 1998-09-28 | Amino terminalmente truncado rantes como antagonistas da quimiocina |
| BR9812394-7A BR9812394A (pt) | 1997-09-29 | 1998-09-28 | Amino terminalmente truncado mcp-2 como antagonistas da quimiocina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9812565-6A BR9812565A (pt) | 1997-09-29 | 1998-09-28 | Amino terminalmente truncado rantes como antagonistas da quimiocina |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US6977071B2 (pt) |
| EP (6) | EP0906954A1 (pt) |
| JP (2) | JP4230659B2 (pt) |
| KR (2) | KR100560275B1 (pt) |
| CN (3) | CN1145693C (pt) |
| AR (2) | AR013528A1 (pt) |
| AT (3) | ATE368742T1 (pt) |
| AU (2) | AU750341B2 (pt) |
| BG (2) | BG64679B1 (pt) |
| BR (2) | BR9812565A (pt) |
| CA (2) | CA2304827A1 (pt) |
| CY (1) | CY1110927T1 (pt) |
| CZ (2) | CZ299478B6 (pt) |
| DE (3) | DE69823218T2 (pt) |
| DK (3) | DK1021541T3 (pt) |
| EA (2) | EA003940B1 (pt) |
| EE (2) | EE200000151A (pt) |
| ES (3) | ES2218860T3 (pt) |
| HU (2) | HU226414B1 (pt) |
| IL (2) | IL135352A (pt) |
| NO (2) | NO20001584D0 (pt) |
| NZ (3) | NZ503234A (pt) |
| PL (2) | PL197569B1 (pt) |
| PT (3) | PT1439231E (pt) |
| SK (2) | SK286439B6 (pt) |
| UA (2) | UA73081C2 (pt) |
| WO (2) | WO1999016876A1 (pt) |
| ZA (2) | ZA988676B (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067117B1 (en) | 1997-09-11 | 2006-06-27 | Cambridge University Technical Services, Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| US6989435B2 (en) | 1997-09-11 | 2006-01-24 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| AU1616499A (en) | 1997-12-01 | 1999-06-16 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Chemokine variants and methods of use |
| US7238711B1 (en) | 1999-03-17 | 2007-07-03 | Cambridge University Technical Services Ltd. | Compounds and methods to inhibit or augment an inflammatory response |
| ATE339504T1 (de) * | 1999-10-25 | 2006-10-15 | Pharis Biotec Gmbh | Prozessiertes menschliches chemokin phc-1 |
| EP1167527A1 (en) * | 2000-06-22 | 2002-01-02 | Euroscreen S.A. | Processed human chemokines PHC-1 and PHC-2 |
| AU2505601A (en) * | 1999-11-15 | 2001-05-30 | Wolf-Georg Forssmann | Novel use of hcc-2 |
| CA2316405A1 (en) * | 2000-05-26 | 2001-11-26 | Ian Clark-Lewis | Modulation of inflammation by protease products |
| EP1176200A3 (de) | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen |
| UA77950C2 (en) * | 2000-10-04 | 2007-02-15 | Applied Research Systems | Use of mutants of cc chemokines for treatment of multiple sclerosis |
| GB2373785A (en) * | 2001-03-28 | 2002-10-02 | Rega Inst For Medical Res | Truncating chemokines using dipeptidyl peptidase IV |
| WO2003051921A1 (en) | 2001-12-17 | 2003-06-26 | Applied Research Systems Ars Holding N.V. | Chemokine mutants acting as chemokine antagonists |
| WO2004104216A2 (en) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| DE102005049637A1 (de) * | 2005-10-14 | 2007-04-26 | Rheinisch-Westfälische Technische Hochschule Aachen | Antagonisten gegen die Interaktion von PF4 und RANTES |
| JP5624884B2 (ja) | 2007-08-02 | 2014-11-12 | ノビミューンエスアー | 抗ｒａｎｔｅｓ抗体およびその使用の方法 |
| WO2011097567A1 (en) * | 2010-02-08 | 2011-08-11 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity |
| EP2545174B1 (en) | 2010-03-11 | 2015-11-11 | Health Research, Inc. | Methods and compositions containing fc fusion proteins for enhancing immune responses |
| TW201718851A (zh) * | 2015-09-18 | 2017-06-01 | 通用醫院公司 | 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途 |
| WO2019229615A1 (en) | 2018-05-28 | 2019-12-05 | Université De Genève | Methods of inhibiting cerebral inflammation |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US11402391B2 (en) | 2020-12-21 | 2022-08-02 | Incelldx, Inc. | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0311107A3 (en) | 1987-10-08 | 1990-04-18 | Stichting REGA V.Z.W. | Anti-hiv active 3'-fluoro-purine-2',3'-dideoxyribosides |
| US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
| HU221089B1 (en) * | 1994-12-08 | 2002-08-28 | Glaxo Group Ltd | Rantes peptide derivates with antagonistic effect and uses thereof |
| WO1997025427A1 (en) * | 1996-01-12 | 1997-07-17 | Genetics Institute, Inc. | Beta-chemokine, h1305 (mcp-2) |
| JP2000508527A (ja) * | 1996-03-27 | 2000-07-11 | アイコス コーポレイション | 単球走化性タンパク質―５物質及び方法 |
| FR2748938B1 (fr) * | 1996-05-22 | 1998-07-31 | Pasteur Institut | Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih |
| US6168784B1 (en) * | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
-
1997
- 1997-09-29 EP EP97116863A patent/EP0906954A1/en not_active Withdrawn
- 1997-12-19 EP EP97122471A patent/EP0905240A1/en not_active Withdrawn
-
1998
- 1998-03-10 EP EP98104216A patent/EP0905241A1/en not_active Withdrawn
- 1998-09-22 ZA ZA9808676A patent/ZA988676B/xx unknown
- 1998-09-22 ZA ZA9808675A patent/ZA988675B/xx unknown
- 1998-09-28 JP JP2000513946A patent/JP4230659B2/ja not_active Expired - Fee Related
- 1998-09-28 AT AT04007579T patent/ATE368742T1/de active
- 1998-09-28 DK DK98947553T patent/DK1021541T3/da active
- 1998-09-28 DK DK04007579T patent/DK1439231T3/da active
- 1998-09-28 CN CNB988095696A patent/CN1145693C/zh not_active Expired - Fee Related
- 1998-09-28 NZ NZ503234A patent/NZ503234A/en unknown
- 1998-09-28 DK DK98951476T patent/DK1019507T3/da active
- 1998-09-28 NZ NZ516027A patent/NZ516027A/en unknown
- 1998-09-28 ES ES98951476T patent/ES2218860T3/es not_active Expired - Lifetime
- 1998-09-28 WO PCT/EP1998/006142 patent/WO1999016876A1/en not_active Ceased
- 1998-09-28 AT AT98951476T patent/ATE263242T1/de active
- 1998-09-28 AU AU97474/98A patent/AU750341B2/en not_active Ceased
- 1998-09-28 PT PT04007579T patent/PT1439231E/pt unknown
- 1998-09-28 CZ CZ20001146A patent/CZ299478B6/cs not_active IP Right Cessation
- 1998-09-28 CA CA002304827A patent/CA2304827A1/en not_active Abandoned
- 1998-09-28 EA EA200000379A patent/EA003940B1/ru not_active IP Right Cessation
- 1998-09-28 CA CA002305017A patent/CA2305017A1/en not_active Abandoned
- 1998-09-28 JP JP2000513947A patent/JP4233214B2/ja not_active Expired - Fee Related
- 1998-09-28 PL PL339559A patent/PL197569B1/pl not_active IP Right Cessation
- 1998-09-28 CN CNB988095726A patent/CN1148447C/zh not_active Expired - Fee Related
- 1998-09-28 PT PT98947553T patent/PT1021541E/pt unknown
- 1998-09-28 BR BR9812565-6A patent/BR9812565A/pt not_active Application Discontinuation
- 1998-09-28 BR BR9812394-7A patent/BR9812394A/pt not_active Application Discontinuation
- 1998-09-28 AT AT98947553T patent/ATE264390T1/de active
- 1998-09-28 EP EP98951476A patent/EP1019507B1/en not_active Expired - Lifetime
- 1998-09-28 EP EP98947553A patent/EP1021541B1/en not_active Expired - Lifetime
- 1998-09-28 PT PT98951476T patent/PT1019507E/pt unknown
- 1998-09-28 ES ES04007579T patent/ES2287601T3/es not_active Expired - Lifetime
- 1998-09-28 KR KR1020007003019A patent/KR100560275B1/ko not_active Expired - Fee Related
- 1998-09-28 KR KR1020007003020A patent/KR100542934B1/ko not_active Expired - Fee Related
- 1998-09-28 DE DE69823218T patent/DE69823218T2/de not_active Expired - Lifetime
- 1998-09-28 WO PCT/EP1998/006143 patent/WO1999016877A1/en not_active Ceased
- 1998-09-28 CZ CZ20001147A patent/CZ299479B6/cs not_active IP Right Cessation
- 1998-09-28 AR ARP980104819A patent/AR013528A1/es active IP Right Grant
- 1998-09-28 EA EA200000378A patent/EA003942B1/ru not_active IP Right Cessation
- 1998-09-28 AR ARP980104820A patent/AR013529A1/es active IP Right Grant
- 1998-09-28 EE EEP200000151A patent/EE200000151A/xx unknown
- 1998-09-28 HU HU0003505A patent/HU226414B1/hu not_active IP Right Cessation
- 1998-09-28 UA UA2000042499A patent/UA73081C2/uk unknown
- 1998-09-28 DE DE69838188T patent/DE69838188T2/de not_active Expired - Lifetime
- 1998-09-28 HU HU0003563A patent/HU226468B1/hu not_active IP Right Cessation
- 1998-09-28 ES ES98947553T patent/ES2215324T3/es not_active Expired - Lifetime
- 1998-09-28 EP EP04007579A patent/EP1439231B1/en not_active Expired - Lifetime
- 1998-09-28 SK SK450-2000A patent/SK286439B6/sk not_active IP Right Cessation
- 1998-09-28 NZ NZ503235A patent/NZ503235A/xx unknown
- 1998-09-28 DE DE69822856T patent/DE69822856T2/de not_active Expired - Lifetime
- 1998-09-28 AU AU94420/98A patent/AU750606B2/en not_active Ceased
- 1998-09-28 UA UA2000042496A patent/UA73080C2/uk unknown
- 1998-09-28 EE EEP200000152A patent/EE200000152A/xx unknown
- 1998-09-28 CN CNB031492991A patent/CN1233415C/zh not_active Expired - Fee Related
- 1998-09-28 PL PL339545A patent/PL196427B1/pl not_active IP Right Cessation
- 1998-09-28 SK SK451-2000A patent/SK286495B6/sk not_active IP Right Cessation
-
2000
- 2000-03-22 BG BG104266A patent/BG64679B1/bg unknown
- 2000-03-22 BG BG104267A patent/BG64757B1/bg unknown
- 2000-03-27 NO NO20001584A patent/NO20001584D0/no not_active Application Discontinuation
- 2000-03-28 US US09/537,858 patent/US6977071B2/en not_active Expired - Fee Related
- 2000-03-28 NO NO20001609A patent/NO20001609D0/no unknown
- 2000-03-28 US US09/537,859 patent/US6905676B2/en not_active Expired - Fee Related
- 2000-03-29 IL IL135352A patent/IL135352A/en not_active IP Right Cessation
- 2000-03-29 IL IL135351A patent/IL135351A/en not_active IP Right Cessation
-
2005
- 2005-03-07 US US11/072,454 patent/US7326411B2/en not_active Expired - Fee Related
- 2005-05-06 US US11/123,089 patent/US7338653B2/en not_active Expired - Fee Related
- 2005-05-18 US US11/131,221 patent/US20050220790A1/en not_active Abandoned
-
2007
- 2007-10-08 CY CY20071101290T patent/CY1110927T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9812394A (pt) | Amino terminalmente truncado mcp-2 como antagonistas da quimiocina | |
| ATE389724T1 (de) | Menschliche dnase i hyperaktive varianten | |
| BR0212897A (pt) | Conjugados de análogos de somatostatina ou bombesina diagnóstica ou terapêutica e usos dos mesmos | |
| DE122005000001I2 (de) | Zweiwertige Metallsalze von 2-N, N-di(carboxymethyl)-amino-3-cyano-4-carboxymethyl-5-carboxy-thiophens{ure, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
| BR0109027A (pt) | Peptìdios derivados de caseìna e usos dos mesmos em terapia | |
| BR0108173A (pt) | Composições farmacêuticas de toxina de botulina | |
| BR0015506A (pt) | Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças | |
| ES2031804T3 (es) | Derivado del activador de plasminogeno de tipo tisular. | |
| BR0009964A (pt) | Peptìdios artificiais com atividade desuperfìcie e sua utilização na preparação de surfactante artificial | |
| ATE125706T1 (de) | Diphosphonate enthaltende pharmazeutische zusammensetzungen zur behandlung von arthrosis. | |
| BRPI0415290A (pt) | uso terapêutico de variantes de quimiocina | |
| BR0013638A (pt) | Novas moléculas semelhantes a interferon beta | |
| DE58902712D1 (de) | N-acetylglucosamin-zubereitungen zur buccalen anwendung. | |
| TR200002078T2 (tr) | Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar. | |
| HRP20030215B1 (en) | Chemokine mutants in the tratment of multiple sclerosis | |
| ATE395602T1 (de) | Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren | |
| BR0006088A (pt) | Derivados de proteìna c | |
| DE69822810D1 (de) | Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x | |
| FR2618677B1 (fr) | Composition pharmaceutique destinee a la prevention et au traitement des maladies bacteriennes ou virales | |
| BR9809457A (pt) | Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia. | |
| DE69816808D1 (de) | Somatostatin agoniste zur reduzierung von körpergewicht | |
| BR0014803A (pt) | Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico | |
| DK0811068T3 (da) | Humane DNase I varianter | |
| ATE410516T1 (de) | Varianten der humanen glycosylphosphatidylinositol-spezifischen phospholipase d und ihre verwendungen | |
| Schmid et al. | Hormonal effects on Na-K-ATPase of various parts of the rat nephron |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: LABORATOIRES SERONO SA (CH) Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |